

## Cystemustine in recurrent high grade glioma

**X. Durando · E. Thivat · H. Roché · J. O. Bay ·  
J.-J. Lemaire · P. Verrelle · J. Chazal ·  
H. Curé · P. Chollet**

Published online: 23 June 2006  
© Springer Science+Business Media B.V. 2006

Journal of Neuro-Oncology  
DOI 10.1007/s11060-005-9096-7

As the contents of our publication were not reviewed nor approved by the EORTC and since M.-A. Lentz has not directly participated in redaction of this article, her name is deleted from the authors' list.

Moreover, we would like to add an acknowledgement to the EORTC-CSG/ECSG group for having given us access to the data of their phase II clinical trial.

---

The online version of the original article can be found at  
<http://dx.doi.org/10.1007/s11060-005-9096-7>

---

X. Durando · E. Thivat · J. O. Bay · P. Verrelle ·  
H. Curé · P. Chollet  
Centre Jean Perrin, 63011, Clermont-Ferrand Cédex,  
France

E. Thivat · P. Chollet  
Inserm, U484, Rue Montalembert, 63011,  
Clermont-Ferrand, France

H. Roché  
Centre Claudius Regaud, 20–24 rue du Pont Saint-Pierre,  
31052, Toulouse Cédex, France

J.-J. Lemaire · J. Chazal  
CHU Hopital Gabriel Montpied, Clermont-Ferrand, France

X. Durando (✉)  
Centre Jean Perrin, 58 Rue Montalembert, BP 392, 63011,  
Clermont-Ferrand Cédex, France  
e-mail: Recherche.CLINIQUE@cjp.fr